[1] Liu Q,Zhang D,Qian H,Chu Y,Yang Y,Shao J .2020 .Superior antitumor efficacy of IFN-α2b-incorporated photo-cross-linked hydrogels combined with T cell transfer and low-dose irradiation against gastric cancer. Int J Nanomedicine, : 3669-80.
[2] Wolffsohn JS,Huarte ST,Jones L,Craig JP,Wang MT .2021 .Clinical practice patterns in the management of dry eye disease: a TFOS international survey. Ocular Surface, 21 : 78-86.
[3] Lewczuk N,Zdebik A,Bogusławska J .2019 .Interferon alpha 2a and 2b in ophthalmology: a review. J Interferon Cytokine Res, 39 : 259-72.
[4] Lewczuk N,Zdebik A,Bogusławska J .2019 .Interferon Alpha 2a and 2b in Ophthalmology: A Review. J Interferon Cytokine Res, 39(5) : 259-72.
[5] Akbari M,Elmi R . .Herpes simplex virus and human papillomavirus coinfections in hyperimmunoglobulin E syndrome presenting as a conjunctival mass lesion. Case Rep Med 2017; Article ID 1650841., : .
[6] Bekisz J,Baron S,Balinsky C,Morrow A,Zoon KC .2010 .Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals, 3 : 994-1015.
[7] Tagliaferri P,Caraglia M,Budillon A,Marra M,Vitale G,Viscomi C .2005 .New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer. Cancer Immunol Immunother, 54 : 1-10.
[8] Akbari M. .2022 .Is there an alternative therapy for refractory vernal keratoconjunctivitis? A case report and review of literature. J Adv Pharm Edu Res, 12 : 54-8.
[9] Gupta S,Singh P,Singh M,Naik M,for Steroid-Resistant VKC .2021 .: Our 2- Year Experience at a Tertiary Health-Care Centre. Clin Ophthalmol, 15 : 2993-9.
[10] Zanjani H,Aminifard MN,Ghafourian A,Pourazizi M,Maleki A,Arish M .2017 .Comparative Evaluation of Tacrolimus Versus Interferon Alpha-2b Eye Drops in the Treatment of Vernal Keratoconjunctivitis: A Randomized, Double-Masked Study. Cornea, 36 : 675-8.
[11] Akbari M. .2022 .Update on overview of pterygium and its surgical management. J Popul Ther Clin Pharmacol, 29 : e30-e45.
[12] Meel R,Dhiman R,Vanathi M,Sen S,Gupta N,Tandon R .2021 .Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists. Oman J Ophthalmol, 14 : 27-32.
[13] Kusumesh R,Ambastha A,Kumar S,Sinha BP,Imam N. .2017 .Retrospective Comparative Study of Topical Interferon α2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia. Cornea, 36 : 327-31.
[14] Raina UK,Pavitra B,Bhattacharya S,Ravinesh K,Goel R .2023 .Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence. Oman J Ophthalmol, 16 : 30-4.
[15] Bolek B,Wylęgała A,Teper S,Kokot J,Wylęgała E .2020 .Treatment of conjunctival papilloma with topical interferon alpha-2b - case report. Medicine (Baltimore), 99(7) : e19181.
[16] Schechter BA,Rand WJ,Velazquez GE,Williams WD,Starasoler L .2002 .Treatment of conjunctival papillomata with topical interferon Alfa-2b. Am J Ophthalmol, 134 : 268-70.
[17] Nuessle S,Auw-Haedrich C,Jiang J,Boehringer D,Reinhard T .2023 .Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions. Graefes Arch Clin Exp Ophthalmol, 261 : 1159-66.
[18] Lachapelle KR,Rathee R,Kratky V,Dexter DF V .2000 .Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b. Arch Ophthalmol, 118 : 284-5.
[19] Ross JJ,Tu KL,Damato BE .2004 .Systemic remission of nonHodgkin's lymphoma after intralesional interferon alpha2b to bilateral conjunctival lymphomas. Am J Ophthalmol, 138 : 672-3.
[20] Gurnani B,Kaur K.,Ocular Surface K. . .Squamous Neoplasia. , : .
[21] Adams CP,Cohen EJ,Albrecht J,Laibson PR .1984 .Interferon treatment of adenoviral conjunctivitis. Am J Ophthalmol, 98 : 429-32.
[22] Meel R,Dhiman R,Vanathi M,Sen S,Gupta N,Tandon R .2021 .Treatment outcome with interferon alpha 2b in ocular surface squamous neoplasia: Recommendation as primary treatment by peripheral ophthalmologists. Oman J Ophthalmol, 14 : 27-32.
[23] Kusumesh R,Ambastha A,Kumar S,Sinha BP,Imam N. .2017 .Retrospective Comparative Study of Topical Interferon α2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia. Cornea, 36 : 327-31.
[24] Chaugule SS,Park J,Finger PT .2018 .Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?. Indian J Ophthalmol, 66 : 55-60.
[25] Galor A,Karp CL,Chhabra S,Barnes S,Alfonso EC .2010 .Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. Br J Ophthalmol, 94 : 551-4.
[26] Raina UK,Pavitra B,Bhattacharya S,Ravinesh K,Goel R .2023 .Topical cyclosporine A and interferon alpha-2b as adjuvants to surgery to decrease pterygium recurrence. Oman J Ophthalmol, 16 : 30-4.
[27] Yin M,Li H,Zhang Y,Dai H,Luo F,Interferon Z. .2019 .Alpha-2b Eye Drops Prevent Recurrence of Pterygium After the Bare Sclera Technique: A Single-Center, Sequential, and Controlled Study. Cornea, 38 : 1239-44.
[28] Schechter BA,Rand WJ,Velazquez GE,Williams WD,Starasoler L .2002 .Treatment of conjunctival papillomata with topical interferon Alfa-2b. Am J Ophthalmol, 134 : 268-70.
[29] Nuessle S,Auw-Haedrich C,Jiang J,Boehringer D,Reinhard T .2023 .Real-life data of adjuvant IFN-α2b and MMC in conjunctival melanocytic lesions. Graefes Arch Clin Exp Ophthalmol, 261 : 1159-66.
[30] Blasi M,Tiberti A,Berarducci A,Balestrazzi E.,Intralesional E. .2006 .Interferon Alfa-2b for Conjunctival MucosaAssociated Lymphoid Tissue Lymphoma. Investigative Ophthalmol Visual Sci, 47 : 2825-9.